新型疫苗治疗急性白血病及多发性骨髓瘤的临床研究

目的　探讨新型疫苗主动治疗急性白血病及多发性骨髓瘤的疗效及毒副作用。方法　应用基因工程生产的细胞因子和急性白血病及多发性骨髓瘤肿瘤细胞制备的疫苗 ,主动免疫治疗急性白血病 7例、多发性骨髓瘤37例。结果　 37例急性白血病患者中化疗未缓解或化疗不能耐受者 2 9例 ,经疫苗治疗达到完全缓解者 5例占17.3% ,部分缓解者 6例占 2 0 .7% ,微效者 4例占 13.8%。总有效率 5 1.8%。化疗缓解组 8例疫苗治疗后维持缓解达 8～ 13个月复发。多发性骨髓瘤 7例 ,其中 1例完全缓解 ,5例部分缓解。治疗中未发现明显副作用。结论　应用新型疫苗治疗化疗无效或化疗不能耐受的急性白血病及多发性骨髓瘤具有肯定疗效。且经济简便 ,无明显毒副作用

Clinical study of treating acute leukemia and multiple myeloma with a novel vaccine

Objective To investigate the efficacy and side effects of treating acute leukemia (AL) and multiple myeloma (MM) with a novel vaccine of active immunization. Methods Thirty seven patients with AL and 7 with MM received the active immunotherapy of the vaccine. The vaccine was produced by tumor cells of AL and cytokine was manufactured by genetic engineering. Results Of the 37 cases of AL, no remission of chemotherapy and intolerance with chemotherapy appeared in 29 cases. Five cases had complete remission by the vaccine therapy (17.3%), 8 had partial remission (20.7%) and 5 had minute remission (13.8%), with the efficiency rate being 51.8%. Another 8 cases receiving active immunity therapy of novel vaccine relapsed until 8～13 months later. Of the 7 cases of MM, 1 case had complete remission and 5 cases had partial remission. No side effects were observed in all the patients receiving vaccine injection. Conclusion The results showed that the active immunotherapy with the novel vaccine has an apparent effect on some patients with AL and MM. In addition, the vaccine therapy is economical and has no side effects.